Shilpa Medicare receives USFDA approval for Bortezomib injection
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
The Dengue IgG/IgM Rapid Test is a diagnostic tool used to detect antibodies against the dengue virus in blood samples
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
Subscribe To Our Newsletter & Stay Updated